NEWS & PERSPECTIVES

Psychedelics News

Curated updates on microdosing, research, policy, and community.

The latest

2026-10-16 • Blossom Pulse: Papers

Serotonergic psychedelics delay resting state neurovascular coupling dynamics

This brain imaging analysis (s=2, n=32) found that LSD and DMT slowed blood-flow responses in brain regions linked to serotonin receptors during rest. Correcting for these vascular effects improved detection of drug-r...

2026-10-16 • Blossom Pulse

Context Shapes Alpha-Band Electrophysiological Signatures Under Psilocybin

This EEG preprint compared baseline with 19 mg oral psilocybin in healthy adults (n=56 for rest, meditation and music; n=53 for movie viewing). Alpha power and connectivity generally fell at rest, while structured con...

2026-10-15 • Lucid News

American Trickster: The Hidden Lives of Carlos Castaneda

A new biography by Ru Marshall examines the long shadow that hoaxer Carlos Castaneda cast on psychedelics and new age spirituality. The post American Trickster: The Hidden Lives of Carlos Castaneda first appeared on L...

Research
2026-10-15 • Psychedelic Press (Substack)

Inner Landscapes: Salvia Divinorum

An interview with Christopher Solomon on healing, embodiment, and harm reduction

2026-10-15 • Psychedelic Invest

SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies

TEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that it will shift its strategic focus toward Agentic AI-powered…

2026-10-15 • Blossom Pulse: Papers

Longitudinal peripheral DNA methylation remodeling following ketamine-assisted psychotherapy in major depressive disorder

This longitudinal study (n=10) examined changes in buccal DNA methylation in adults with major depressive disorder receiving three sessions of intranasal ketamine alongside structured psychotherapy. Depressive symptom...

2026-10-15 • Blossom Pulse

Baseline Response Criterion and Changes in Emotional Bias as Markers of Esketamine Response in Treatment-Resistant Depression

This study (n=53) compared emotional face processing in people with treatment-resistant depression and healthy controls before and during 4 weeks of esketamine treatment. A lower baseline response criterion was associ...

2026-10-15 • Blossom Pulse

NRx Pharmaceuticals received an FDA review letter requesting only minor labelling changes for preservative-free ketamine NRX-100 ahead of the 10 November 2026 GDUFA goal date.

The FDA requested minor label changes and submission of labels using NRX-100’s proprietary product name, which remains under review. NRx Pharmaceuticals is completing final manufacturing process validation runs and ai...

2026-10-15 • Blossom Pulse

Longitudinal peripheral DNA methylation remodeling following ketamine-assisted psychotherapy in major depressive disorder

This longitudinal study (n=10) examined changes in buccal DNA methylation in adults with major depressive disorder receiving three sessions of intranasal ketamine alongside structured psychotherapy. Depressive symptom...

2026-10-15 • Blossom Pulse: Papers

Baseline Response Criterion and Changes in Emotional Bias as Markers of Esketamine Response in Treatment-Resistant Depression

This study (n=53) compared emotional face processing in people with treatment-resistant depression and healthy controls before and during 4 weeks of esketamine treatment. A lower baseline response criterion was associ...

2026-10-14 • DoubleBlind Magazine

Indigenous People’s Day Ain’t Over Yet

And other parties happening in New York this week after Horizons: Perspectives on Psychedelics. [...] Read More...

2026-10-14 • Seeing What Is There (Substack)

Why You Should Not Subscribe to the Metropolitan Review

The endless upward fail of the white male elite in America

2026-10-14 • Psychedelic Invest

Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day

LONDON & JERSEY CITY, N.J., October 14, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today…

2026-10-14 • Blossom Pulse

Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Net…

This qualitative study (n=4) explored former psychedelic-trial participants’ experiences of recruitment, preparation, dosing, integration and study ending. Participants said communication, staff relationships, uncerta...